I suspect either the partner is focused on PrEP. I
Post# of 148184
Quote:
I suspect either the partner is focused on PrEP. I know companies like Gilead think that is the future, so they may be more interested in that than mono. Meaning the potential partner is pushing this harder.
If the deal is with a company that is already in the HIV space this may be a way for them to delay profit on their drug(s) being sacrificed.